RevaTis SA
4.9 FTEThe score of RevaTis shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +3 % Total assets +17 % Headcount (avg FTE) -11 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
RevaTis's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −620,715 € | ||||
| Equity | €2.55m | ||||
| Cash | 371,672 € | ||||
| EBITDA | −280,709 € | ||||
| Total assets | €4.12m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Jul 2026
- Year ended 31 Dec 2024filed on 12 Nov 2025
- Year ended 31 Dec 2023filed on 29 Jul 2024
- Year ended 31 Dec 2022filed on 12 Jul 2023
- Year ended 31 Dec 2021filed on 06 Jul 2022
RevaTis's financial analysis
- Solvency62.0%sector median: 34.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of RevaTis
RevaTis's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0541.682.642
- VAT number
- BE0541682642
- Peppol
- Registered · 0208:0541682642 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 06 Nov 2013
- Registered office
- 6900 Marche-en-Famenne
- Size
- Micro · 4.9 FTE
- Latest accounts
- 2025 · filed on 28 Jul 2026
- Activity
- Manufacture of medicaments (NACE 21201)
RevaTis (SA) has been based in Marche-en-Famenne since 2013, active in: manufacture of medicaments. For 2025, it reports a net loss of 620,715 € and equity of €2.55m; its revenue is not published. With 4.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 62.0%, above the median of its sector (34.4%).
Companies similar to RevaTis
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Alnylam Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet €1.20m
- Surveal Pharma Wholesale of pharmaceutical and medical goods Ixelles · balance sheet €5.47m
- Sasmar Pharmaceuticals Wholesale of pharmaceutical and medical goods Overijse · balance sheet €3.07m
- Dermax Wholesale of pharmaceutical and medical goods Liège · balance sheet €5.73m
- Vetria Wholesale of pharmaceutical and medical goods Beernem · balance sheet €5.19m
- Schwabe Pharma Belgium Wholesale of pharmaceutical and medical goods Kontich · balance sheet €3.13m
- Swiftpharma Wholesale of pharmaceutical and medical goods Genk · balance sheet €4.90m
Frequently asked questions about RevaTis
What is the revenue of RevaTis?
RevaTis files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of RevaTis?
In Belgium, the VAT number is the company number prefixed with BE: BE0541682642 for RevaTis, if the company is VAT-registered. Its company number (CBE) is 0541.682.642.
Where is the registered office of RevaTis?
According to the CBE register, the registered office of RevaTis is in 6900 Marche-en-Famenne.
What is the equity of RevaTis?
At the close of the 2025 financial year, the equity of RevaTis amounts to 2,551,321 €, a solvency of 62.0% of total assets.
How many people work at RevaTis?
4.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages RevaTis?
The register lists 9 active mandates at RevaTis. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of RevaTis
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →